IPO Boutique

Akcea Therapeutics, Inc. IPO Advisory

Share this IPO Profile:

Smart Search
Company begins with...
Company contains...

For IPO Boutique's "scale of 1 to 5" BUY rating on Akcea Therapeutics, Inc., and our comprehensive analysis, click "Buy Market Research".
Company
Symbol
Price Range
Issue Price
Open
Shares
Trade Date
Akcea Therapeutics, Inc.AKCA -
NASDAQ
$12.00-$14.00 $8.00 $8.1315.63 million7/14/2017
Cowen and Company, Stifel, Wells Fargo Securities
Co-Manager(s):
BMO Capital Markets
Health Care
Filing(s):

Filed 2017-03-27
Underwriter Added 2017-05-09
Terms Added 2017-06-20



Akcea Therapeutics, Inc. Quote & Chart - Click for current quote - AKCA

About Akcea Therapeutics, Inc. (adapted from Akcea Therapeutics, Inc. prospectus):
They are a late-stage biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders.

This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.



IPO Boutique aggregates information on public companies and private companies, such as "AKCA" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.

Used our Comprehensive Single Promo Advisory and want more?
We also offer a monthly or annual subscription






© 2005 - 2024 IPO Boutique. All Rights Reserved